Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18701700 | 0.88 | DPP4 (0.40) | DPP4RIPK1MEN1KMT2AGPR119 | |
| SCHEMBL24339766 | 0.82 | RIPK1 (0.51) | DPP4RIPK1MEN1KMT2AGPR119 | |
| SCHEMBL13888052 | 0.82 | RIPK1 (0.46) | DPP4RIPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL24339741 | 0.82 | EPHX2 (0.44) | DPP4RIPK1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL20469332 | 0.79 | DPP4 (0.40) | DPP4RIPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL24339765 | 0.79 | GNAI3 (0.49) | DPP4RIPK1MEN1KMT2A | |
| SCHEMBL22657455 | 0.78 | MEN1 (0.39) | DPP4RIPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL2674022 | 0.77 | RECQL (0.59) | GPR119RECQLSMN1; SMN2 | |
| SCHEMBL18701704 | 0.76 | HSD11B1 (0.49) | RIPK1ALDH1A1CNR2 | |
| SCHEMBL18701702 | 0.76 | HSD11B1 (0.49) | RIPK1ALDH1A1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130060013-A1 | Compounds useful for treating neurodegenerative disorders | SATORI PHARMACEUTICALS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130060013-A1 | Compounds useful for treating neurodegenerative disorders | SNCA, HTT, CLN6 | DPP4 1127/4885RIPK1 4241/4885MEN1 2565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.